Physician profile
Mark R Walker
NPI 1407876907
$24,025.19
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $9,508 · 2020: $14K · 2021: $641.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $16,838.68 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $5,663.18 | 2019-2021 | |
| Lilly USA, LLC | $561.73 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $506.46 | 2019-2021 | |
| Pfizer INC. | $149.01 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $101.49 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $70.32 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $38.55 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $25.65 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $24.69 | 2019 | |
| Eli Lilly and Company | $18.31 | 2019-2021 | |
| Tactile Systems Technology INC | $15.15 | 2019 | |
| Amarin Pharma, INC. | $11.97 | 2019 |
Research and ownership
$2,845.10 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.